XCHC Releases Worldwide Growth Guidance For Its Cannabinoid Treatment Centers and Formulations Targeting Critical Human Ailments, Company Acts on Own Guidance
DALLAS, Feb. 21, 2013 /PRNewswire/ — X-Change Corp. (NASDAQ OTC: XCHC), a patient based U.S. company targeting critical and non-critical ailments through the use of Cannabinoid based formulations, extracts, and products through multiple Phytiva Brand product lines and solutions, is pleased to release its analysis of the worldwide market potential for medical Cannabinoid treatments of critical ailments and acute disease.
The amount of money needed on a worldwide basis for treating critical and non-critical ailments is unnecessary, wasteful, and inhumane. The Company’s near-term, global mission is to advance affordable and effective treatment solutions for a wide variety of ailments, as outlined below, using Cannabinoids. A comparative cost analysis shows a dramatic difference in treatment cost for most ailments between the status quo and the Company’s approach. Therefore, the Company intends to use this massive differential, which is essentially a large profit base, through which to expand operations by opening multiple treatment facilities locally and internationally at a rapid rate.
The Company has already publicly launched two initiatives with its Phytiva Brand European Cannabinoid product line and its Cannabinoid treatment-based facility development agreement with the Maliseet Nation in Eastern Canada.
These are two examples of the Company’s targeted investments demonstrating a solid commitment to innovation in seizing opportunities in the quickly emerging Cannabinoid based treatment market. And the market opportunities are substantial:
AIDS $12.6 In 2010, $12.6 billion treatment market. TechNavio's analysts forecast the global HIV drug market to reach $15.5 billion by 2014. Alzheimer's $8.3 The global Alzheimer's disease treatment market was valued at $8.3 billion in 2010 and estimated to be $9.0 billion by 2016. Anti- $50.0 With annual estimates nearing $50 Aging billion a year, the market for global Anti-Aging products expected to reach $291.9 billion by 2015. Overall sales in the Asthma and COPD drug market worth $25 billion in 2008, increasing to an estimated $26 billion in 2009. By 2014, this market is projected to increase to $31 billion, for a 5-year compound annual growth Asthma $25.0 rate (CAGR) of 3.3%. Arthritis $35.0 Global market for arthritis drugs valued at $35 billion in 2008. Cancer $75.0 Global sales of cancer drugs expected to grow at a compounded annual rate of 12 to 15 percent, reaching $75 to $80 billion this year. Chronic Pain Management globally recorded sales Pain of $22.0 billion in 2010; rising at a Management compound annual growth rate (CAGR) of 8.9% market value is set to contract $22.0 to $18.7 billion by 2016. In 2009, the Diabetes treatment market generated worldwide sales of over $25 billion. Datamonitor expects the antidiabetics market will grow to $34.8 billion in 2019 for the seven Diabetes $25.0 major markets. Digestive The global market for medical enzymes Diseases is estimated at $6 billion in 2010. The market is growing at a compounded annual rate (CAGR) of 3.9%, to reach $7.2 billion in 2015. Therapeutic enzymes are the biggest segment in terms of revenues generated. This sector was valued at $5.3 billion in 2010 and is expected to increase at a 3.6% compound. Enzymes used in molecular research expected to experience the fastest compound annual growth rate (CAGR) of 6.2%, over the study period. This sector was valued at $546 million in 2010 and expected $6.0 to reach $739 million by 2015. Glaucoma $14.0 Over $14 billion in 2009. The global Glaucoma pharmaceuticals market is projected to exceed $3.35 billion by 2015. High $25.0 The prescription drug market for the Blood treatment of Hypertension is estimated Pressure to continue to rise in value from $25 billion today. Influenza $28.0 In 2009, the global market for antiviral drugs attained total sales of over $28 billion. Multiple The Multiple Sclerosis (MS) treatments Sclerosis market is one of the largest for CNS disorders, with total pharmaceutical revenues of over $8 billion in 2009. Revenues for MS treatments will rise $8.0 significantly from 2010 to 2025. PTSD $72.0 $72 billion from top ten drug sales - and rising.
X-Change Corp. President & CEO Robert Kane stated, “Global demand for Cannabinoid based treatments is growing exponentially and is reaching into the hundreds of billions of dollars. The demand for Cannabinoid treatments is at an all-time high, as clinicians, scientists, and patients are discovering or rediscovering their efficacy. The treatment cost-based comparisons give us an inherent advantage within the current market structures, and thus we believe that our mission will succeed: the Company mission is to become one of the leading providers of Cannabinoid treatments. Through our partnerships and associations, we believe that the Company is already growing at such a substantial rate that we will have a truly positive impact on the healthcare industry and on fundamental human health treatments and options.”
About Phytiva Brand Product Lines
Phytiva expects to develop and launch various innovative product lines. The first is the Phytiva Brand European Line, which is an inventive line that is a hybrid of a proven, existing product line that has been well-managed and conservatively-run for over a decade with a Cannabinoid based product line, utilizing the unique and potent benefits of Cannabinoids. Phytiva’s revolutionary formulations target not just the symptom, but also the cause. Cannabinoids and their sources constitute an ideal base for therapeutic solutions and have been utilized for centuries in skin and other remedies.
In the near term, Phytiva strives to be one of the quintessential cosmeceutical and nutraceutical brands in the world. As cosmetics and nutrition are personal, over-the-counter markets, they continuously evolve with the introduction of new formulations and products, creating a multibillion-dollar global market opportunity. The Company believes that Phytiva’s lines will capture a substantial and profitable portion of that market, as Phytiva becomes a household name.
About The X-Change Corporation
X-Change Corp. is U.S. Boutique Company whose niche is Cannabinoid based extracts and products that target medical cannabis, cosmeceutical, nutraceutical, and social usage solutions through multiple Phytiva Brand product lines, products, and services. These new Phytiva lines will be launched with Cannabinoid based formulations through the launching of a combination of retail and wholesale products, medical cannabis dispensaries, cannabis research in clinics and laboratories, as announced for example with the Maliseet Nation in Canada, and other legal state and foreign grow operations, on a jurisdiction by jurisdiction approved basis.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. X-Change Corp. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
President & CEO
SOURCE X-Change Corp.